Author's response to reviews

Title: Gemcitabine versus gemcitabine based combination chemotherapy in advanced pancreatic cancer- Indirect comparison

Authors:

Asma Sultana (asmasul@liv.ac.uk)
Paula Ghaneh (P.Ghaneh@liverpool.ac.uk)
David Cunningham (David.Cunningham@rmh.nhs.uk)
Naureen Starling (Naureen.Starling@rmh.nhs.uk)
John P Neoptolemos (j.p.neoptolemos@liv.ac.uk)
Catrin Tudur Smith (cat1@liverpool.ac.uk)

Version: 3 Date: 9 June 2008

Author's response to reviews: see over
6th June 2008

The Editor,

BMC Cancer

Re: MS: 8540915911643260- Gemcitabine based combination chemotherapy in advanced pancreatic cancer- Indirect comparison, Sultana A et al.

Authors’ responses to the reviewers.

Referee 1 –Discretionary revision

Ref. [2] has been published in the meanwhile, and final survival data would be available. Perhaps the authors may finally wish to adapt the discussion section (p. 8) and also delete Ref. [6].

Response

The full publication of reference 2 is acknowledged, and the survival data available from the publication has been used to obtain a hazard ratio for the direct comparison of gemcitabine and capecitabine versus gemcitabine and oxaliplatin (page 6). The discussion has also been amended (pages 7 and 8) to include this, and reference 6 deleted.